Pre-earnings options volume in Sellas Life Sciences is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 15.4%, or 0c, after results are released. Median move over the past eight quarters is 19.7%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
- Sellas Life Sciences announces preliminary data from Phase 2a t rial of SLS009
- Sellas Life Sciences announces positive review of ongoing Phase 3 REGAL trial
- SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
- Largest borrow rate increases among liquid names